Shared and unique transcriptomic signatures of antidepressant and probiotics action in the mammalian brain

To comprehensively characterize the intrinsic molecular effects of ADs independently of the specifics of particular disease models, we generated 300 transcriptomic profiles from 10 brain regions in naïve rats. Three classical tricyclic antidepressants as Bupropion, desipramine, fluoxetine and a probiotic formulation (Lacidofil®) massively altered gene expression in most regions [>1,500 differentially expressed genes (DEGs)], suggesting that traditional single-gene or single-pathway analyses may under-represent the complexity of molecular responses. To complement our multi-regional epigenome and transcriptome map of chronic fluoxetine action (Rayan et al. Mol Psychiatry (2022). https://doi.org/10.1038/s41380-022-01725-1), we used bulk RNA-seq to profile the Bupropion-, Desipramine-, Fluoxetine-, Maltodextrin- and Probiotic- induced genome-wide transcriptome changes (post 3 week treatment) in 10 brain regions. Here we deposit these RNA-seq profiles (10 regions, 6 treatment groups, 5 replicates; 10*6*5= 300 profiles). To reduce the effects of inter-animal biological variation, each RNA-seq sample was pooled from 2 animals (60 animals in total).